10x Genomics is trading 4.32% up at $74.55 on October 21, 2026, with the move appearing consistent with positive biotech-sector sentiment rather than a direct company catalyst.
- No clear company-specific announcement explaining the move surfaced, and its latest listed company news predates today.
- Coverage cited Merck KGaA’s agreement to acquire Silence Therapeutics and positive Phase 3 trial news as sector catalysts; third-quarter results are scheduled for November 5.